Intravenous paracetamol in patients undergoing major abdominal surgery

Not Applicable

Completed

• Conditions: sepsis; Anaesthesiology - Pain management; Surgery - Other surgery; Major abdominal surgery; pharamacokinetics and metabolism

• Registration Number: ACTRN12608000028303
• Lead Sponsor: Dunedin School of Medicine, University of Otago

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-01-18
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Adults undergoing major abdominal surgery

Exclusion Criteria

history of past or present ethanol or substance misuse; nutritional deficiency; hepatic disease, including history of hepatitis B or C; previous adverse reaction to paracetamol; comedication with enzyme inducing or inhibiting drugs, including barbiturates, phenytoin and rifampicin.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rine levels of paracetamol metbolites at 2, 4, 6 hours[After 1st dose and after 1st dose on 3rd day];Blood levels of paracetamol at 0, 10, 20, 40, 60, 90, 120, 240 and 360 minutes[After the 1st dose and on 3rd day (after 1st dose)]

Secondary Outcome Measures

Name	Time	Method
blood cytokine levels, IL-6, TNF-a, IL-8, IL-1b, IL-10 and IL-12(p70) will be assayed using multiplex biometric enzyme-linked immunosorbant assay (ELISA)-based immunoassay[once daily on postoperative days 1-3];pain scores[once daily on postoperative days 1-3];'sickness score' scale based on vital signs and biochemical parameters[once daily on postoperative days 1-3]